CTLA4 targeted therapy plus PD-1 targeted therapy could benefit women with ovarian cancer
An analysis of the NRG Oncology clinical trial NRG-GY003 suggests that adding ipilimumab, a monoclonal antibody that targets the protein receptor CTLA-4, to a regimen...









